Schmid R A, Zollinger A, Singer T, Hillinger S, Leon-Wyss J R, Schöb O M, Høgåsen K, Zünd G, Patterson G A, Weder W
Department of Surgery, University Hospital Zürich, Switzerland.
J Thorac Cardiovasc Surg. 1998 Jul;116(1):90-7. doi: 10.1016/S0022-5223(98)70246-6.
Soluble complement receptor type 1 inhibits complement activation by blocking C3 and C5 convertases of the classical and alternative pathways. We evaluated the effect of soluble complement receptor type 1 on lung allograft reperfusion injury.
Left lung transplantation was performed in 13 weight-matched pigs (25 to 31 kg) after prolonged preservation (20 hours at 1 degree C). One hour after reperfusion the recipient contralateral right lung was excluded to assess graft function only. Complement activity and C3a levels were measured after reperfusion and at the end of the assessment. Extravascular lung water index, intrathoracic blood volume, and cardiac output were assessed during a 5-hour observation period. Gas exchange and hemodynamics were monitored. At the end of the 5-hour assessment period, myeloperoxidase assay and bronchoalveolar lavage were performed to assess neutrophil migration, and C5b-9 (membrane attack complex) deposits in the allograft were detected by immunohistochemistry. Two groups were studied. In group II (n = 6) recipient animals were treated with soluble complement receptor type 1 (15 mg/kg) 15 minutes before reperfusion. Group I (n = 7) served as the control group.
Serum complement activity was completely inhibited in group II. In contrast to group I, C5b-9 complexes were not detected in group II allograft tissue samples. C3a was reduced to normal levels in group II (p = 0.00005). Extravascular lung water index was higher in group I animals throughout the assessment period (p = 0.035). No significant difference in allograft myeloperoxidase activity (p = 0.10) and polymorphonuclear leukocyte count of the bronchoalveolar lavage fluid (p = 0.057) was detected.
Inhibition of the complement system by soluble complement receptor type 1 blocks local complement activation in the allograft and reduces posttransplantation reperfusion edema but does not improve hemodynamic parameters.
可溶性补体受体1通过阻断经典途径和替代途径的C3和C5转化酶来抑制补体激活。我们评估了可溶性补体受体1对肺移植再灌注损伤的影响。
对13只体重匹配(25至31千克)的猪进行左肺移植,供肺经过长时间保存(1℃下保存20小时)。再灌注1小时后,仅评估受体对侧右肺以评估移植肺功能。在再灌注后及评估结束时测量补体活性和C3a水平。在5小时的观察期内评估血管外肺水指数、胸腔内血容量和心输出量。监测气体交换和血流动力学。在5小时评估期结束时,进行髓过氧化物酶测定和支气管肺泡灌洗以评估中性粒细胞迁移,并通过免疫组织化学检测移植肺中C5b - 9(膜攻击复合物)的沉积。研究分为两组。在第二组(n = 6)中,受体动物在再灌注前15分钟接受可溶性补体受体1(15毫克/千克)治疗。第一组(n = 7)作为对照组。
第二组血清补体活性被完全抑制。与第一组相比,在第二组移植肺组织样本中未检测到C5b - 9复合物。第二组中C3a降至正常水平(p = 0.00005)。在整个评估期内,第一组动物的血管外肺水指数较高(p = 0.035)。在移植肺髓过氧化物酶活性(p = 0.10)和支气管肺泡灌洗液中多形核白细胞计数(p = 0.057)方面未检测到显著差异。
可溶性补体受体1对补体系统的抑制作用可阻断移植肺中的局部补体激活,并减少移植后再灌注水肿,但不能改善血流动力学参数。